Verisante Technology, a provider of cancer detection technology, has entered into an exclusive agreement with Frontière Médicale EUROPE to distribute Verisante Aura in the UK and Ireland.
Verisante Aura is meant for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma. It is used when a medical professional intends to obtain additional information to rule out one of the above conditions before making a final decision to biopsy.
Aura is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate results.
The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.
Verisante president and CEO Thomas Braun said, "Frontmed has extensive knowledge of the market for dermatological and skin care devices, and a breadth of experience in facilitating the market penetration of new technologies. Frontmed will distribute Aura and also support technical training and servicing throughout the UK and Ireland."
Frontmed co-founder Daniel Krelle said that the Aura's impressive clinical study results show it can quickly and accurately assist in diagnosing all the major forms of skin cancer, including melanoma, basal cell carcinoma and squamous cell carcinoma.
"Aura should be welcomed by doctors and clinics across the UK and Ireland as an additional tool to assist in the biopsy decision," Krelle added.
With a value of $78bn, the European medical device market represents 30% of the world over market, next to the US.
